Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral NCX-1000 dose-escalation study in portal hypertension
2005-003483-31Phase 2Completed
- Sponsor
- Axcan Pharma Inc.
- Start
- Oct 2005
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind, single-arm trial of NCX-1000 in Portal Hypertension (PH), sponsored by Axcan Pharma Inc. Primary endpoint: Fasting hepatic venous pressure gradient. Started Oct 2005; status: completed.
02
Drugs
NCX-1000
03
Conditions
Portal Hypertension (PH)
Beyond the preview
Go deeper on 2005-003483-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003483-31.